In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation (D. Mass.)

As class counsel, we were actively involved in helping to secure a $72.5 million settlement for a class of direct purchasers alleging that a brand-name pharmaceutical
manufacturer paid its generic competition to stay off the market, which in turn inflated the price of certain skin medication.

Scroll to Top